Two-year follow-up of pulmonary arterial hypertension patients treated with sildenafil;Seguimento de dois anos em pacientes com hipertensão arterial pulmonar sob tratamento com sildenafila

Arquivos Brasileiros de Cardiologia

Volumn 94, Issue 5, 2010, Pages 671-677

  Franchi, Sonia Meiken ^a   Barreto, Alessandra Costa ^a   Cícero, Cristina ^a   Castro, Claudia Regina Pinheiro ^a   De Sá Ribeiro, Zilma Verçosa ^a   Lopes, Antonio Augusto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hypertension; Hypertension, pulmonary; Phosphodiesterase inhibitors analysis; Vasodilator agents; Vital capacity

Indexed keywords

ANTICOAGULANT AGENT; SILDENAFIL;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DYSPNEA; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HOT FLUSH; HUMAN; IDIOPATHI PULMONARY HYPERTENSION; IDIOPATHIC PULMONARY HYPERTENSION; MALE; MIGRAINE; MONOTHERAPY; MORTALITY; MYALGIA; NAUSEA; OXYGEN SATURATION; PHYSICAL CAPACITY; PULMONARY HYPERTENSION; PULSE OXIMETRY; RATING SCALE; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL DISORDER; WALKING;

EID: 77953732287     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/s0066-782x2010005000041     Document Type: Article

References (23)

1. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996; 334: 296-302.
2. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347: 322-9.
3. Galiè N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebocontrolled trial. J Am Coll Cardiol. 2002; 39: 1496-502.
4. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165: 800-4.
5. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346: 1258.
6. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 169: 441-7.
7. Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005; 46: 529-35.
8. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2006; 354:2400-1.
9. Ghofrani HA, Rose F, Schermuly RT, olschewski H, Wiedemann R, Kreckel A, et al. oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol. 2003; 42: 158-64.
10. Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J. 2007; 29: 469-75.
11. Barreto AC, Franchi SM, Castro CR, Lopes AA. one-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease. Braz J Med Biol Res. 2005; 38: 185-95.
12. Hoeper MM, Dinh-Xuan AT. Combination therapy for pulmonary arterial hypertension: still more questions than answers. Eur Respir J. 2004; 24: 339-40.
13. ATS Committee on Proficiency Standards For Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166: 111-7.
14. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982; 14: 377-81.
15. Macchia A, Marchioli R, Marfisi R, Scarano M, Levantesi G, Tavazzi L, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J. 2007; 153: 1037-47.
16. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006; 174: 1257-63.
17. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005; 25: 942.
18. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007; 116: 238-48.
19. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007; 131: 1917-28. (Pubitemid 46981654)
20. Klepetko W, Mayer E, Sandoval J, Trulock EP, Vachiery JL, Dartevelle P, et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43 (12 Suppl S):73S-80S.
21. Law MA, Grifka RG, Mullins CE, Nihill MR. Atrial septostomy improves survival in select patients with pulmonary hypertension. Am Heart J. 2007; 153: 779-84.
22. Hertz MI, Taylor Do, Trulock EP, Boucek MM, Mohacsi PJ, Edwards LB, et al. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant. 2002; 21: 950-70.
23. Hertz MI, Mohacsi PJ, Taylor Do, Trulock EP, Boucek MM, Deng MC, et al. The registry of the International Society for Heart and Lung Transplantation: introduction to the Twentieth Annual Reports-2003. J Heart Lung Transplant. 2003; 22: 610-5.